AI-extracted from the 10-Q filed 2026-08-06 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Celldex reported Q2 net loss of $73.5M on minimal revenue of $22K, with R&D expenses up 25% YoY to $67.5M driven by Phase 3 barzolvolimab trials; cash position strengthened to $717.6M via $323.8M April equity raise.
Biggest Revenue Drivers
Product development and licensing agreements$7Kflat YoY
Contracts and grants$15K-98% YoY
Decrease in revenue from Rockefeller University contract manufacturing and R&D services
Biggest Revenue Drivers
Total revenue: $22K-97% YoY
Product development and licensing agreements$7Kflat YoY
Contracts and grants$15K-98% YoY
Decrease in revenue from Rockefeller University contract manufacturing and R&D services
Largest Expense Items
Research and development$67.5M+25% YoY
Primarily due to increased barzolvolimab clinical trial and product development expenses
General and administrative$13.1M+26% YoY
Higher commercial planning expenses and increased employee headcount
Watch Items from the Filing
Phase 3 barzolvolimab trials (EMBARQ-CSU) enrolled 1,939 patients across 43 countries; topline data expected Sept/Oct 2026. Enrollment complete Feb 2026. BLA filing planned for 2027.
Company projects cash sufficient through 2028; net cash burn was $123M in H1 2026. Future liquidity dependent partly on $52.5M regulatory milestone payment timing and form (cash/stock choice).
Barzolvolimab Phase 2 prurigo nodularis trial failed primary and secondary endpoints in July 2026; company discontinued program indicating mast cell may not be key driver.
Company raised $323.8M net proceeds via April 2026 underwritten offering of 11.9M shares; ATM facility of $300M remains available.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
Neil Garry ArthurReporting ownerGrant or award · Jun 25, 2026
Jain RitaReporting ownerGrant or award · Jun 25, 2026
Torres DeniceReporting ownerGrant or award · Jun 25, 2026
Marucci Anthony SPRESIDENT & CEOGrant or award · Jun 25, 2026
Keler TiborEXECUTIVE VP & CSOGrant or award · Jun 25, 2026
About Celldex Therapeutics, Inc. (CLDX): stock profile, AI score and financials
Celldex Therapeutics, Inc. (CLDX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CLDX at 7.9/100 on a composite quality score built from its SEC filings, placing it at rank #2,898 of 2,925 stocks — the bottom half of the AI-ranked universe. CLDX scores in the top quartile across institutional flow (95.1). Areas of concern include profitability (0.1) and free cash flow (0.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 0.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Celldex Therapeutics, Inc. reports quarterly revenue of $22.0K, net income of $-73.5M, free cash flow of $-60.6M. Top institutional holders of CLDX by reported 13-F value include WELLINGTON MANAGEMENT GROUP LLP, BlackRock, Kynam Capital Management, based on the most recent SEC filings. CLDX trades on the Nasdaq exchange and files with the SEC under CIK 744218. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CLDX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Celldex Therapeutics, Inc. directly from SEC EDGAR.